

RDIF, UNICEF ink Sputnik V vaccine supply agreement

28 May 2021 | News

For the supply of 220 million doses of two-dose Sputnik V Russian COVID-19 vaccine



Human Vaccine LLC, a wholly owned subsidiary of the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) has announced the signing of an agreement for the supply of 220 million doses of two-dose Sputnik V Russian COVID-19 vaccine with the United Nations International Children's Emergency Fund (UNICEF). This amount is sufficient to vaccinate 110 million people.

The supply agreement with UNICEF for Sputnik V vaccine will broaden access to help meet vaccine demand around the world. Procurement and delivery of the vaccine by UNICEF is subject to the vaccine receiving WHO Emergency Use Listing.

The decision is expected soon on the Sputnik V application for WHO Emergency Use Listing that was submitted in October 2020.

Concurrently, RDIF will be holding a separate discussion with Gavi, the Vaccine Alliance to see the Sputnik V vaccine considered for inclusion in the COVAX Facility's Portfolio of COVID-19 vaccines.

The COVAX Facility (co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO) together with UNICEF aims to help end the acute phase of the global pandemic by the end of 2021 by providing rapid, fair and equitable access to safe and effective vaccines to all participating countries and territories regardless of income level, thus enabling the protection of frontline health care and social workers, as well as other high-risk and vulnerable groups.